Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418853 | 0.83 | CETP (0.33) | CD44CYP3A4TSHRALDH1A1HPGD | |
| SCHEMBL2666086 | 0.80 | CD44 (0.34) | CD44CYP3A4TSHRALDH1A1HPGD | |
| SCHEMBL30677836 | 0.77 | FFAR4 (0.37) | MPOADORA2AATRBACE1HTR1A | |
| SCHEMBL423294 | 0.75 | ADORA2A (0.35) | MPOADORA2ABACE1HTR1ADRD2 | |
| SCHEMBL5325701 | 0.75 | MPO (0.33) | MPOADORA2AATRHTR1ADRD2 | |
| SCHEMBL6264335 | 0.75 | AHR (0.45) | MPOHTR1ADRD2HTR2AGPR3 | |
| SCHEMBL18866953 | 0.75 | ALDH1A1 (0.45) | HTR1ACD44CYP3A4TSHRALDH1A1 | |
| SCHEMBL3151886 | 0.75 | FFAR4 (0.34) | MPOADORA2AATRHTR1ADRD2 | |
| SCHEMBL13551133 | 0.75 | MPO (0.33) | MPOADORA2AATRHTR1ADRD2 | |
| SCHEMBL978248 | 0.75 | MPO (0.33) | MPOADORA2AATRHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000027394-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2000-05-18 | — | — | WO | claimed |
| EP-0198797-A2 | Parasiticide | CIBA-GEIGY AG (CH) | 1986-10-22 | — | — | EP | claimed |
| JP-5155879-A | — | — | None | — | — | JP | disclosed |
| EP-4688751-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250368659-A1 | Antiviral Heterocyclic Compounds | ENANTA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2025-08-28 | — | — | US | disclosed |
| US-12358921-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2025063272-A1 | NICOTINAMIDE DERIVATIVE AND AGRICULTURAL AND HORTICULTURAL PLANT DISEASE CONTROL AGENT | クミアイ化学工業株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025036382-A1 | SULFONAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海复宏汉霖生物医药有限公司 | 2025-02-20 | — | — | WO | disclosed |
| EP-4504707-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-4925840-A | FUNGICIDES | CIBA-GEIGY CORPORATION (US) | 1990-05-15 | — | — | US | disclosed |
| EP-0198797-B1 | PARASITICIDE | CIBA-GEIGY AG (CH) | 1990-01-31 | — | — | EP | disclosed |
| US-4859783-A | INTERMEDIATE FOR PESTICIDES | CIBA-GEIGY CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| US-4859783-A | INTERMEDIATE FOR PESTICIDES | CIBA-GEIGY CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| US-4859783-A | INTERMEDIATE FOR PESTICIDES | CIBA-GEIGY CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| US-4780551-A | 2,3-(DIFLUOROMETHYLENEDIOXY)CINNAMONITRILE; FUNGICIDES | CIBA-GEIGY CORPORATION (US) | 1988-10-25 | — | — | US | disclosed |
| US-4722935-A | 2,2-DIFLUORO-4-(2*,4*-DINITRO-6*-TRIFLUOROMETHYLANILINO)-1, 3-BENZODIOXOLE | CIBA-GEIGY CORPORATION (US) | 1988-02-02 | — | — | US | disclosed |
| US-4705800-A | Difluorbenzodioxyl cyanopyrrole microbicidal compositions | CIBA-GEIGY CORPORATION (US) | 1987-11-10 | — | — | US | disclosed |
| EP-0206999-A2 | Microbiocide compounds | CIBA-GEIGY AG (CH) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | MPO 4262/4885ADORA2A 2115/4885ATR 1158/4885 |
| US-12358921-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | MPO 164/4885ADORA2A 1661/4885ATR 3370/4885 |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | MPO 4279/4885ADORA2A 2078/4885ATR 1166/4885 |
| US-20250368659-A1 | Antiviral Heterocyclic Compounds | ACE, HPRT1, ACE2 | MPO 164/4885ADORA2A 1661/4885ATR 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.